Year 2022 / Volume 29 / Supplement 1

Abstract PDF HTML

Cannabinoids Article

Medical cannabis treatment in patients with visceral chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 32-42 / DOI: 10.20986/resed.2022.4030/2022

Raquel Abalo, Jesús de Santiago


ABSTRACT

Chronic visceral pain is very common and disabling. Chronic secondary visceral pain must be distinguished from chronic primary visceral pain states that are considered diseases in their own right. Primary chronic visceral pain is a category of nociplastic-like pain, characterized by impaired nociception without clear evidence of actual or potential tissue damage. Management of primary chronic visceral pain is challenging, either due to lack of pharmacological efficacy or intolerance to side effects. In this context, treatment with cannabinoids can be a useful alternative in these patients.
In this review, after briefly explaining the pathophysiological mechanisms involved in chronic visceral pain and its relationship with the endocannabinoid system, we will show the current evidence on the use of cannabinoids in the treatment of chronic visceral pain.



RESUMEN

El dolor visceral crónico es muy frecuente e incapacitante. El dolor visceral secundario crónico debe distinguirse de los estados de dolor visceral primario crónico, que se consideran enfermedades por derecho propio. El dolor visceral crónico primario es una categoría del dolor de tipo nociplástico, que se caracteriza por una nocicepción alterada sin evidencia clara de daño tisular real o potencial.
El manejo del dolor visceral crónico primario es un desafío, ya sea por falta de eficacia farmacológica o por intolerancia de los efectos secundarios. En este contexto, el tratamiento con cannabinoides puede ser una alternativa útil en estos pacientes.
En esta revisión, tras explicar brevemente los mecanismos fisiopatológicos implicados en el dolor visceral crónico y su relación con el sistema endocannabinoide, revisaremos la evidencia actual sobre la utilización de cannabinoides en el tratamiento del dolor crónico visceral.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Olesen AE, Farmer AD, Olesen SS, Aziz Q, Drewes AM. Management of chronic visceral pain. Pain Manag. 2016;6(5):469-86.
DOI: 10.2217/pmt-2015-0011
2. Fitzcharles MA, Petzke F, Tölle TR, Häuser W. Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain. Drugs. 2021;81(18):2103-16.
DOI: 10.1007/s40265-021-01602-1
3. Taylor C, Birch B. Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review. Urology. 2021;148:8-25.
DOI: 10.1016/j.urology.2020.10.024
4. Abalo R, Martín-Fontelles MI. Cannabis, cannabinoids and visceral pain. En: Preedy VR (editor). The comprehensive handbook of Cannabis related pathology. UK: Elsevier; 2017. p. 439-49.
5. Aziz Q, Giamberardino MA, Barke A, Korwisi B, Baranowski AP, Wesselmann U, et al. The IASP classification of chronic pain for ICD-11: chronic secondary visceral pain. Pain. 2019;160(1):69-76.
DOI: 10.1097/j.pain.0000000000001362
6. Labanski A, Langhorst J, Engler H, Elsenbruch S. Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary challenge. Psychoneuroendocrinology. 2020;111:104501.
DOI: 10.1016/j.psyneuen.2019.104501
7. Zhou Q, Verne GN. Epigenetic modulation of visceral nociception. Neurogastroenterol Motil. 2022:e14443.
DOI: 10.1111/nmo.14443
8. Arslan D, Ünal Çevik I. Interactions between the painful disorders and the autonomic nervous system. Agri. 2022;34(3):155-65.
DOI: 10.14744/agri.2021.43078
9. Gottfried-Blackmore A, Habtezion A, Nguyen L. Noninvasive vagal nerve stimulation for gastroenterology pain disorders. Pain Manag. 2021;11(1):89-96.
DOI: 10.2217/pmt-2020-0067
10. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016:S0016-5085(16)00223-7.
11. López-Gómez L, Bagüés A, Uranga JA, Abalo R. Preclinical models of irritable bowel síndrome. En: Fichna J (Coord.). A Comprehensive Overview of Irritable Bowel Syndrome: Clinical and Basic Science Aspects. Ed. Elsevier; 2020. p. 233-76.
12. Greaves E, Rosser M, Saunders PTK. Endometriosis-Associated Pain - Do Preclinical Rodent Models Provide a Good Platform for Translation? Adv Anat Embryol Cell Biol. 2020;232:25-55.
13. Sofia RD, Vassar HB, Knobloch LC. Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia. 1975;40(4):285-95.
DOI: 10.1007/BF00421466
14. Booker L, Naidu PS, Razdan RK, Mahadevan A, Lichtman AH. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alcohol Depend. 2009;105(1-2):42-7.
DOI: 10.1016/j.drugalcdep.2009.06.009
15. Fowler CJ, Naidu PS, Lichtman A, Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol. 2009;156(3):412-9.
DOI: 10.1111/j.1476-5381.2008.00029.x
16. Harris HM, Rousseau MA, Wanas AS, Radwan MM, Caldwell S, Sufka KJ, et al. Role of Cannabinoids and Terpenes in Cannabis-Mediated Analgesia in Rats. Cannabis Cannabinoid Res. 2019;4(3):177-82.
DOI: 10.1089/can.2018.0054
17. Michalski CW, Laukert T, Sauliunaite D, Pacher P, Bergmann F, Agarwal N, et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology. 2007;132(5):1968-78.
DOI: 10.1053/j.gastro.2007.02.035
18. Zhang L, Kline RH 4th, McNearney TA, Johnson MP, Westlund KN. Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis. Mol Pain. 2014;10:66.
DOI: 10.1186/1744-8069-10-66
19. Ravnefjord A, Brusberg M, Kang D, Bauer U, Larsson H, Lindström E, et al. Involvement of the transient receptor potential vanilloid 1 (TRPV1) in the development of acute visceral hyperalgesia during colorectal distension in rats. Eur J Pharmacol. 2009;611(1-3):85-91.
DOI: 10.1016/j.ejphar.2009.03.058
20. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil. 2006;18(10):949-56.
DOI: 10.1111/j.1365-2982.2006.00819.x
21. Yu Y, Tsang QK, Jaramillo-Polanco J, Lomax AE, Vanner SJ, Reed DE. Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice. J Neurosci. 2022;42(33):6313-24.
DOI: 10.1523/JNEUROSCI.0641-22.2022
22. Coelho A, Wolf-Johnston AS, Shinde S, Cruz CD, Cruz F, Avelino A, et al. Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels. Br J Pharmacol. 2015;172(7):1691-9.
DOI: 10.1111/bph.12958
23. Bercík P, Wang L, Verdú EF, Mao YK, Blennerhassett P, Khan WI, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127(1):179-87.
DOI: 10.1053/j.gastro.2004.04.006
24. Hong S, Fan J, Kemmerer ES, Evans S, Li Y, Wiley JW. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut. 2009;58(2):202-10.
DOI: 10.1136/gut.2008.157594
25. Pierce AN, Di Silvestro ER, Eller OC, Wang R, Ryals JM, Christianson JA. Urinary bladder hypersensitivity and dysfunction in female mice following early life and adult stress. Brain Res. 2016;1639:58-73.
DOI: 10.1016/j.brainres.2016.02.039
26. Iuvone T, Affaitati G, De Filippis D, Lopopolo M, Grassia G, Lapenna D, et al. Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells. Pain. 2016;157(1):80-91.
DOI: 10.1097/j.pain.0000000000000220
27. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 2002;121(1-2):173-90.
DOI: 10.1016/S0009-3084(02)00154-8
28. Lian J, Casari I, Falasca M. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract. Pharmacol Res. 2022;175:106025.
DOI: 10.1016/j.phrs.2021.106025
29. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153(2):263-70.
DOI: 10.1038/sj.bjp.0707486
30. Blanton HL, Barnes RC, McHann MC, Bilbrey JA, Wilkerson JL, Guindon J. Sex differences and the endocannabinoid system in pain. Pharmacol Biochem Behav. 2021;202:173107.
DOI: 10.1016/j.pbb.2021.173107
31. Kwok CH, Devonshire IM, Imraish A, Greenspon CM, Lockwood S, Fielden C, et al. Age-dependent plasticity in endocannabinoid modulation of pain processing through postnatal development. Pain. 2017;158(11):2222-32.
DOI: 10.1097/j.pain.0000000000001027
32. Park Y, Watkins BA. Endocannabinoids and aging-Inflammation, neuroplasticity, mood and pain. Vitam Horm. 2021;115:129-72.
33. Vasileiou I, Fotopoulou G, Matzourani M, Patsouris E, Theocharis S. Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases. Expert Opin Ther Targets. 2013;17(4):363-77.
DOI: 10.1517/14728222.2013.754426
34. Weaver KR, Melkus GD, Fletcher J, Henderson WA. Relevance of Sex and Subtype in Patients With IBS: An Exploratory Study of Gene Expression. Biol Res Nurs. 2020;22(1):13-23.
DOI: 10.1177/1099800419889189
35. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids. 2002;66(2-3):243-56.
DOI: 10.1054/plef.2001.0362
36. Sharkey KA, Wiley JW. The Role of the Endocannabinoid System in the Brain-Gut Axis. Gastroenterology. 2016;151(2):252-66.
DOI: 10.1053/j.gastro.2016.04.015
37. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35-7.
DOI: 10.1038/nm1521
38. Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28-37.
DOI: 10.1097/j.pain.0000000000001390
39. Ford AC, Lacy BE, Talley NJ. Irritable Bowel syndrome. N Engl J Med. 2017;376:2566-78.
DOI: 10.1056/NEJMra1607547
40. van Orten-Luiten AB, de Roos NM, Majait S, Witteman BJM, Witkamp RF. Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. Cannabis Cannabinoid Res. 2022;7(4):436-44.
DOI: 10.1089/can.2020.0087
41. Desai P, Mbachi C, Vohra I, Salazar M, Mathew M, Randhawa T, et al. Association Between Cannabis Use and Healthcare Utilization in Patients With Irritable Bowel Syndrome: A Retrospective Cohort Study. Cureus. 2020;12(5):e8008.
DOI: 10.7759/cureus.8008
42. Carrubba AR, Ebbert JO, Spaulding AC, DeStephano D, DeStephano CC. Use of Cannabis for Self-Management of Chronic Pelvic Pain. J Womens Health (Larchmt). 2021;30(9):1344-51.
DOI: 10.1089/jwh.2020.8737
43. Wagenlehner FME, van Till JWO, Houbiers JGA, Martina RV, Cerneus DP, Melis JHJM,et al. Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. Randomized Controlled Trial. Urology. 2017;103:191-7.
DOI: 10.1016/j.urology.2017.02.029
44. Burstein SH. Ajulemic acid: potential treatment for chronic inflammation. Pharmacol Res Perspect. 2018;6(2):e00394.
DOI: 10.1002/prp2.394
45. Farquhar-Smith WP, Rice AS. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 2001;94(3):507-13.
DOI: 10.1097/00000542-200103000-00023
46. Rankin L, Fowler CJ. The Basal Pharmacology of Palmitoylethanolamide. Int J Mol Sci. 2020;21(21):7942.
DOI: 10.3390/ijms21217942
47. Liang AL, Gingher EL, Coleman JS. Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review. Obstet Gynecol. 2022;139(2):287-96.
DOI: 10.1097/AOG.0000000000004656
48. Indraccolo U, Indraccolo SR, Mignini F. Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: a meta-analysis. Ann Ist Super Sanita. 2017;53(2):125-34.
49. Mistry M, Simpson P, Morris E, Fritz AK, Karavadra B, Lennox C, et al. Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain. J Minim Invasive Gynecol. 2022;29(2):169-76.
DOI: 10.1016/j.jmig.2021.11.017
50. Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23(10):891-6.
DOI: 10.1097/MEG.0b013e328349bb4c
51. Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, Konikoff FM, Ringel Y. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019;31(11):1376-81.
DOI: 10.1097/MEG.0000000000001565
52. Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, et al. A randomized, double-blind, placebo-controlled, parallel group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24(4):714-24.
DOI: 10.1093/ibd/izy002

Artículos relacionados

Pain trajectories and neuropathic pain symptoms following lung cancer surgery: a prospective cohort study

Rev. Soc. Esp. Dolor. 2023; 30(4): 270-283 / DOI: 10.1002/ejp.2265

Fibromyalgia, mitochondrial dysfunction, oxidative stress and inflammation: ozone as a multitarget treatment. Case report and review of literature

Rev. Soc. Esp. Dolor. 2023; 30(4): 258-264 / DOI: 10.20986/resed.2023.3987/2022

Continuous electrical stimulation for the treatment of trigeminal neuralgia. A systematic review

Rev. Soc. Esp. Dolor. 2023; 30(4): 217-226 / DOI: 10.20986/resed.2023.4043/2022

Ultrasound-guided ankle nerve block as adjuvant therapy in chronic pain after occupational injury.

Rev. Soc. Esp. Dolor. 2023; 30(3): 178-186 / DOI: 10.20986/resed.2023.4035/2022

Impact on quality of life, depression and analgesic use, are associated with suffering in fibromyalgia patients. A cross-sectional study

Rev. Soc. Esp. Dolor. 2023; 30(3): 159-167 / DOI: 10.20986/resed.2023.4061/2023

Pain paths among post-COVID-19 condition subjects: a prospective cross-sectional study with in-person evaluation

Rev. Soc. Esp. Dolor. 2023; 30(2): 131-145 / DOI: 10.1002/ejp.2094

Pharmacogenetics in analgesic response: towards a sex-differences personalized medicine

Rev. Soc. Esp. Dolor. 2023; 30(2): 115-124 / DOI: 10.20986/resed.2023.4042/2022

Superior hypogastric plexus block for the management of non-oncological chronic pelvic pain: effectiveness and safety

Rev. Soc. Esp. Dolor. 2023; 30(2): 109-114 / DOI: 10.20986/resed.2023.4038/2022

Pulsed radiofrequency of the supraescapular nerve in the treatment of painful shoulder

Rev. Soc. Esp. Dolor. 2023; 30(1): 36-48 / DOI: 10.20986/resed.2023.4046/2022

Can suicidal behaviour in chronic pain patients be prevented?

Rev. Soc. Esp. Dolor. 2023; 30(1): 5-6 / DOI: 10.20986/resed.2023.4080/2023

Efficacy of physiotherapy on the anxiety and depression in patients with chronic pain: a systematic review

Rev. Soc. Esp. Dolor. 2022; 29(3): 157-168 / DOI: 10.20986/resed.2022.3994/2022

Psychological intervention program to promoted active coping in patients with chronic back pain

Rev. Soc. Esp. Dolor. 2022; 29(3): 149-156 / DOI: 10.20986/resed.2022.3993/2022

The biopsychosocial nature of chronic pelvic floor pain: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 97-113 / DOI: 10.20986/resed.2022.3981/2022

Myofascial pain syndrome in the female pelvic floor musculature. Narrative review of the literature

Rev. Soc. Esp. Dolor. 2022; 29(2): 88-96 / DOI: 10.20986/resed.2022.3970/2022

Cross-sectional study on factors related to chronic pain and its care, according to sex

Rev. Soc. Esp. Dolor. 2022; 29(2): 61-70 / DOI: 10.20986/resed.2022.3968/2022

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Practical aspects of product selection and titration with medical cannabis for chronic pain management

Rev. Soc. Esp. Dolor. 2022; 29(13): 43-51 / DOI: 10.20986/resed.2022.4031/2022

Is medical cannabis useful for the treatment of fibromyalgia?

Rev. Soc. Esp. Dolor. 2022; 29(13): 27-31 / DOI: 10.20986/resed.2022.4029/2022

Cannabinoids in neuropathic pain: lights and shadows

Rev. Soc. Esp. Dolor. 2022; 29(13): 20-26 / DOI: 10.20986/resed.2022.4027/2022

Medical cannabis and cancer: benefits for cancer pain and other related symptoms

Rev. Soc. Esp. Dolor. 2022; 29(13): 14-19 / DOI: 10.20986/resed.2022.4026/2022

Current evidence of medical cannabis treatment in patients with chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 10-13 / DOI: 10.20986/resed.2022.4024/2022

Some preclinical results of cannabinoids and pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 3-9 / DOI: 10.20986/resed.2022.4033/2022

Lights and shadows of treating pain with medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 1-2 / DOI: 10.20986/resed.2022.4036/2022

Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

Rev. Soc. Esp. Dolor. 2022; 29(1): 51-55 / DOI: 10.20986/resed.2021.3930/2021

Complex regional pain syndrome, rehabilitation, pharmacotherapy, psychology.

Rev. Soc. Esp. Dolor. 2022; 29(1): 34-50 / DOI: 10.20986/resed.2022.3978/2022

Recommendations for the safe prescription of opioids in patients with a history or risk of abuse

Rev. Soc. Esp. Dolor. 2021; 28(6): 343-349 / DOI: 10.20986/resed.2022.3935/2021

Preliminary study on the evaluation of mechanical pressure pain and central pain modulation mechanisms by algometry in an anesthesia unit

Rev. Soc. Esp. Dolor. 2021; 28(6): 311-318 / DOI: 10.20986/resed.2022.3885/2021

Thalalgic triad. A new clinical entity from a case series

Rev. Soc. Esp. Dolor. 2021; 28(5): 276-281 / DOI: 10.20986/resed.2021.3941/2021

Efficacy and complications of analgesic techniques for the treatment of moderate to severe postoperative acute pain

Rev. Soc. Esp. Dolor. 2021; 28(5): 264-265 / DOI: 10.20986/resed.2021.3942/2021

Descriptive study on the profile of patients sent to the Chronic Pain Treatment Unit of the University Hospital of Gran Canaria Dr. Negrín (UTDC-HUGCDN) as a basis for the reorganization of this

Rev. Soc. Esp. Dolor. 2021; 28(5): 254-263 / DOI: 10.20986/resed.2021.3939/2021

The unsolved problem of postoperative pain: critical analysis and prospects for improvement

Rev. Soc. Esp. Dolor. 2021; 28(4): 232-238 / DOI: 10.20986/resed.2021.3917/2021

Clinical recommendations for rehabilitation of people with fibromyalgia. A narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 194-210 / DOI: 10.20986/resed.2021.3932/2021

Psychological factors associated with the adherence to analgesic treatment in patients with chronic pain: systematic review of the literature

Rev. Soc. Esp. Dolor. 2021; 28(4): 181-193 / DOI: 10.20986/resed.2021.3922/2021

Does it decrease the efficacy or safety of COVID-19 vaccines in patients with chronic pain?

Rev. Soc. Esp. Dolor. 2021; 28(2): 115-116 / DOI: 10.20986/resed.2021.3933/2021

Risk of misuse of prescribed opioids in patients with chronic noncancer pain in a workers compensation system hospital in Chile

Rev. Soc. Esp. Dolor. 2021; 28(2): 82-91 / DOI: 10.20986/resed.2021.3845/2020

Analgesic effectiveness of tapentadol in neuropathic pain secondary to post-laminectomy syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 71-75 / DOI: 10.20986/resed.2021.3822/2020

Parsonage-turner after rabies vaccination due to bat bite: case report

Rev. Soc. Esp. Dolor. 2021; 28(1): 57-61 / DOI: 10.20986/resed.2021.3832/2020

Inflammatory mediators: its connection with chronic pain and associated problems. Review

Rev. Soc. Esp. Dolor. 2021; 28(1): 37-46 / DOI: 10.20986/resed.2021.3841/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

Central sensitization in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 31-37 / DOI: 10.20986/resed.2021.3876/2020

Experimental models for pain evaluation in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 18-30 / DOI: 10.20986/resed.2021.3872/2020

Adaptation of the chronic pain unit of the Hospital Complex from Vigo to the state of alarm due to the SARS-CoV-2 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(6): 392-393 / DOI: 10.20986/resed.2020.3827/2020

Transitional pain clinic

Rev. Soc. Esp. Dolor. 2020; 27(6): 369-374 / DOI: 10.20986/resed.2020.3840/2020

Calcific tendinitis of the shoulder: risk factors and effectiveness of iontophoresis with acetic acid 5 % plus ultrasound: prospective quasi-experimental study at 5 years with 138 cases

Rev. Soc. Esp. Dolor. 2020; 27(6): 340-348 / DOI: 10.20986/resed.2020.3842/2020

School of non-oncologic chronic pain patients and opioid treatment

Rev. Soc. Esp. Dolor. 2020; 27(5): 324-328 / DOI: 10.20986/resed.2020.3804/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Therapeutic failure of the lumbar medial branch block and its relation to obesity. Retrospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 298-305 / DOI: 10.20986/resed.2020.3829/2020

Efficacy of lidocaine perfusions in fibromyalgia: a prospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 287-291 / DOI: 10.20986/resed.2020.3796/2020

Pain: a "hotchpotch"

Rev. Soc. Esp. Dolor. 2020; 27(4): 278-280 / DOI: 10.20986/resed.2016.3507/2016

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Clinical pathophysiology in patients with sickle cell disease: the transition from acute to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 257-268 / DOI: 10.20986/resed.2020.3814/2020

Gender determinants in the approach to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 252-256 / DOI: 10.20986/resed.2020.3802/2020

Incidence of postmastectomy pain syndrome. Retrospective analysis

Rev. Soc. Esp. Dolor. 2020; 27(4): 246-251 / DOI: 10.20986/resed.2020.3797/2020

Sociodemographic and clinical characterization in patients with chronic back pain, Cienfuegos 2019

Rev. Soc. Esp. Dolor. 2020; 27(4): 239-245 / DOI: 10.20986/resed.2020.3798/2020

Spinal cord stimulation. Analysis of the diagnostic indications

Rev. Soc. Esp. Dolor. 2020; 27(4): 234-238 / DOI: 10.20986/resed.2020.3777/2019

Suboccipital decompression as an alternative in the treatment of pain secundary to occipital neuralgia: a case series

Rev. Soc. Esp. Dolor. 2020; 27(3): 221-226 / DOI: 10.20986/resed.2020.3791/2020

Spanish Pain Society (SPS). Healthcare recommendations for pain units in the face of progressive normalization of activity during the COVID-19 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(3): 192-215 / DOI: 10.20986/resed.2020.3821/2020

Drug consumption used for musculoskeletal pain treatment in a cohort of blue-collar workers in Zaragoza (Spain)

Rev. Soc. Esp. Dolor. 2020; 27(3): 150-159 / DOI: 10.20986/resed.2020.3749/2019

COVID-19 coronavirus and chronic pain: uncertainties

Rev. Soc. Esp. Dolor. 2020; 27(2): 72-73 / DOI: 10.20986/resed.2020.3808/2020

Conventional radiofrequency for genicular nerves in treatment of knee osteoarthritis

Rev. Soc. Esp. Dolor. 2020; 27(1): 59-60 / DOI: 10.20986/resed.2016.3515/2016

Effectiveness of patient-controlled analgesia in acute and chronic pain after cardiac surgery: a prospective study

Rev. Soc. Esp. Dolor. 2020; 27(1): 24-36 / DOI: 10.20986/resed.2020.3747/2019

Correlation study between diagnostic opportunity and pain severity in patients with fibromyalgia who enter the Nononcological Chronic Pain Unit at the San Borja Arriarán Clinical Hospital

Rev. Soc. Esp. Dolor. 2019; 26(6): 331-336 / DOI: 10.20986/resed.2019.3690/2018

Connexins in chronic pain. A new target?

Rev. Soc. Esp. Dolor. 2019; 26(6): 322-323 / DOI: 10.20986/resed.2019.3785/2019

Validation of the coping strategies to chronic pain reduced questionnaire in the cienfuegan population with chronic back pain (2017-2018)

Rev. Soc. Esp. Dolor. 2019; 26(5): 276-283 / DOI: 10.20986/resed.2019.3732/2019

The use of new technologies in patients with chronic pain. A reality that cannot be denied

Rev. Soc. Esp. Dolor. 2019; 26(5): 259-260 / DOI: 10.20986/resed.2019.3766/2019

Orofacial pain in the dental clinic

Rev. Soc. Esp. Dolor. 2019; 26(4): 233-242 / DOI: 10.20986/resed.2019.3724/2019

Role of depressive symptomatology, catastrophism and expectation in the efficacy of interventional treatment in chronic low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 227-232 / DOI: 10.20986/resed.2019.3704/2018

Characterization of pain in patients with breast cancer attending the Oncology Unit of the San José Hospital

Rev. Soc. Esp. Dolor. 2019; 26(4): 221-226 / DOI: 10.20986/resed.2019.3692/2018

The new international classification of diseases (ICD-11) and chronic pain. Pragmatical implications

Rev. Soc. Esp. Dolor. 2019; 26(4): 209-210 / DOI: 10.20986/resed.2019.3752/2019

Manual therapy, a double-edged weapon in the management of chronic pain

Rev. Soc. Esp. Dolor. 2019; 26(3): 206-207 / DOI: 10.20986/resed.2018.3675/2018

Opioid tapering may improve outcomes for chronic pain patients

Rev. Soc. Esp. Dolor. 2019; 26(3): 204-205 / DOI: 10.20986/resed.2017.3615/2017

Myofascial pain syndrome as a cause of postoperative acute pain in hip surgery

Rev. Soc. Esp. Dolor. 2019; 26(2): 117-119 / DOI: 10.20986/resed.2019.3655/2018

Effectiveness of hand crossing to produce analgesia in patients with chronic pain of the upper limb

Rev. Soc. Esp. Dolor. 2019; 26(2): 81-88 / DOI: 10.20986/resed.2019.3674/2018

Profiles of personality and resilience in chronic pain: utility of the CDRISC-10 to discriminate between resilient and vulnerable types

Rev. Soc. Esp. Dolor. 2019; 26(2): 72-80 / DOI: 10.20986/resed.2018.3670/2018

Opioids and addiction in chronic pain: is it a problem?, how to address it?

Rev. Soc. Esp. Dolor. 2019; 26(2): 65-67 / DOI: 10.20986/resed.2019.3736/2019

Oxytocin and chronic pain in humans

Rev. Soc. Esp. Dolor. 2019; 26(1): 52-58 / DOI: 10.20986/resed.2018.3664/2018

Effects of multimodal treatment in patients with complex regional pain syndrome type 1 with, at least, 6 months of evolution: a descriptive study

Rev. Soc. Esp. Dolor. 2019; 26(1): 6-13 / DOI: 10.20986/resed.2018.3651/2018

Opinaudit study: clinical uses in breakthrough pain, is scientific evidence being followed up?

Rev. Soc. Esp. Dolor. 2018; 25(6): 325-334 / DOI: 10.20986/resed.2018.3634/2017

Use of major opioids for control of pain in hospitalized patients

Rev. Soc. Esp. Dolor. 2018; 25(6): 318-324 / DOI: 10.20986/resed.2018.3629/2017

Radiofrequency thermal and splanchnics nerves block

Rev. Soc. Esp. Dolor. 2018; 25(5): 303-304 / DOI: 10.20986/resed.2016.3509/2016

Implications of bioethics in the treatment of chronic pain: the change of paradigms

Rev. Soc. Esp. Dolor. 2018; 25(5): 291-300 / DOI: 10.20986/resed.2018.3666/2018

Pain in the elderly and in patients with cognitive deficit. A DELPHI study

Rev. Soc. Esp. Dolor. 2018; 25(5): 251-262 / DOI: 10.20986/resed.2017.3621/2017

Chrono study: prevalence of breakthrough pain among patients with non-cancer chronic pain in Andalusia, Spain

Rev Soc Esp Dolor 2018; 25(4): 214-221 / DOI: 10.20986/resed.2017.3626/2017

Trial therapy on laterality and motor imagery and selective glenohumeral muscle activation in patients with massive rotator cuff tear: case series

Rev Soc Esp Dolor 2018; 25(4): 197-206 / DOI: 10.20986/resed.2017.3610/2017

Sex and pain: sexual satisfaction and sexual function in a sample of patients with chronic, non-pelvic pain

Rev Soc Esp Dolor 2018; 25(3): 145-154 / DOI: 10.20986/resed.2018.3600/2017

Painometer v2®: a mobile application certified for monitoring patients with pain

Rev Soc Esp Dolor 2018; 25(2):112-120 / DOI: 10.20986/resed.2017.3555/2016

Potential uses of Mirtazapine in palliative care beyond its antidepressant effect

Rev Soc Esp Dolor 2018; 25(1): 37-44 / DOI: 10.20986/resed.2017.3575/2017

CAD-R. Chronic pain coping questionnaire: confirmatory factor analysis. Are there individual differences in gender, age and type of pain?

Rev Soc Esp Dolor 2017; 24(5): 224-233 / DOI: 10.20986/resed.2017.3558/2016

Intervention of manual motor skill exercises on pain and functionality in adults subjects with rheumatoid arthritis: case series

Rev Soc Esp Dolor 2017; 24(6): 294-303 / DOI: 10.20986/resed.2017.3576/2017

Chronic pain: relationship with prefrontal symptoms and perceived stress

Rev Soc Esp Dolor 2017; 24(4): 179-187 / DOI: 10.20986/resed.2017.3540/2016

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Prescribing strong opioids in patients with non-cancer pain: a description of their characteristics in an area of primary healthcare assistance

Rev Soc Esp Dolor 2017; 24(1): 19-26 / DOI: 10.20986/resed.2016.3471/2016

Instrucciones para citar

Abalo R, de Santiago J. Medical cannabis treatment in patients with visceral chronic pain. Rev Soc Esp Dolor 2022; 29(13): 32-42 / DOI: 1020986/resed20224030/2022


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 9441 veces.
Este artículo ha sido descargado 0 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 20/09/2022

Publicado: 28/10/2022


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
Send by e-mail
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

       Indexada en:
Política de Privacidad